Who are TEZ/IVA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Symdeko (Copackaged), IVA, TEZ, Ivacaftor/Ataluren, LUM/IVA, Ivacaftor+lumacaftor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tez-iva.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

TEZ/IVA — Competitive Intelligence Brief

TEZ/IVA (TEZ/IVA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR modulator. Area: Pulmonology.

phase 3 CFTR modulator CFTR Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

TEZ/IVA (TEZ/IVA) — Vertex Pharmaceuticals Incorporated. TEZ/IVA is a combination of tezacaftor and ivacaftor, which work together to increase the function of the CFTR protein in the lungs.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TEZ/IVA TARGET	TEZ/IVA	Vertex Pharmaceuticals Incorporated	phase 3	CFTR modulator	CFTR
Symdeko (Copackaged)	TEZACAFTOR	Vertex Pharms	marketed		CFTR	2018-01-01
IVA	IVA	Vertex Pharmaceuticals Incorporated	marketed	CFTR potentiator	CFTR (cystic fibrosis transmembrane conductance regulator)
TEZ	TEZ	Vertex Pharmaceuticals Incorporated	marketed	CFTR corrector	CFTR (cystic fibrosis transmembrane conductance regulator)
Ivacaftor/Ataluren	Ivacaftor/Ataluren	University of Alabama at Birmingham	marketed	CFTR modulator combination	CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)
LUM/IVA	LUM/IVA	Vertex Pharmaceuticals Incorporated	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
Ivacaftor+lumacaftor	Ivacaftor+lumacaftor	Assistance Publique - Hôpitaux de Paris	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-06 — Symdeko (Copackaged) · 8354427 · US
2026-12-28 — Symdeko (Copackaged) · 9931334 · US
2026-12-28 — Symdeko (Copackaged) · 9670163 · US
2026-12-28 — Symdeko (Copackaged) · 8754224 · US
2026-12-28 — Symdeko (Copackaged) · 8410274 · US
2027-04-09 — Symdeko (Copackaged) · 10239867 · US
2027-04-09 — Symdeko (Copackaged) · 9974781 · US
2027-04-09 — Symdeko (Copackaged) · 11639347 · US
2027-04-09 — Symdeko (Copackaged) · 10022352 · US
2027-05-01 — Symdeko (Copackaged) · 8598181 · US
2027-05-01 — Symdeko (Copackaged) · 7645789 · US
2027-05-01 — Symdeko (Copackaged) · 8623905 · US
2027-05-20 — Symdeko (Copackaged) · 7495103 · US
2027-06-03 — Symdeko (Copackaged) · 7776905 · US
2027-08-05 — Symdeko (Copackaged) · 8324242 · US
2027-11-12 — Symdeko (Copackaged) · 8415387 · US
2029-08-13 — Symdeko (Copackaged) · 11564916 · US
2029-08-13 — Symdeko (Copackaged) · 10646481 · US
2031-03-25 — Symdeko (Copackaged) · 10081621 · US
2031-03-25 — Symdeko (Copackaged) · 11578062 · US
2033-07-15 — Symdeko (Copackaged) · 10058546 · US
2033-07-15 — Symdeko (Copackaged) · 9012496 · US
2035-04-14 — Symdeko (Copackaged) · 10206877 · US

Sponsor landscape (CFTR modulator class)

Vertex Pharmaceuticals Incorporated · 5 drugs in this class
Chiesi Farmaceutici S.p.A. · 1 drug in this class
Children's Hospital Medical Center, Cincinnati · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TEZ/IVA — Competitive Intelligence Brief. https://druglandscape.com/ci/tez-iva. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab